Compare PXED & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | TBPH |
|---|---|---|
| Founded | 1976 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 993.7M |
| IPO Year | 2025 | N/A |
| Metric | PXED | TBPH |
|---|---|---|
| Price | $32.49 | $17.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $45.00 | $27.80 |
| AVG Volume (30 Days) | 107.6K | ★ 535.4K |
| Earning Date | 11-20-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 3.51 | 0.58 |
| Revenue | ★ $1,007,192,000.00 | $80,327,000.00 |
| Revenue This Year | $4.15 | $70.78 |
| Revenue Next Year | $4.77 | N/A |
| P/E Ratio | ★ $9.27 | $31.31 |
| Revenue Growth | 6.02 | ★ 27.12 |
| 52 Week Low | $23.52 | $7.90 |
| 52 Week High | $47.08 | $20.33 |
| Indicator | PXED | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.95 |
| Support Level | N/A | $17.25 |
| Resistance Level | N/A | $20.32 |
| Average True Range (ATR) | 0.00 | 0.72 |
| MACD | 0.00 | -0.27 |
| Stochastic Oscillator | 0.00 | 21.01 |
Phoenix Education Partners Inc is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. It is one of the online education providers and a pioneer in its field, the company benefits from the dynamic interplay between technological innovation, education, employment and economic trends. It is focused on delivering a personalized, career-relevant and affordable education to its students through its flexible learning model, skills-aligned curriculum and accessible tuition costs.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).